![]() ![]() However, because Roundup remains on the market and because there is a 10-year to 15-year lag between exposure and the onset of symptoms, Bayer also faces years of future litigation from people who use glyphosate on their lawns and farms.īayer said Chhabria's order "closes the door" on using a class action to settle those future claims.īayer said it "will immediately engage with partners to discuss the future of glyphosate-based products in the U.S. The company has resolved all but 30,000 of those claims. The company committed $9.6 billion in June to settle around 125,000 existing claims and lawsuits by Roundup users who were already alleging the product caused their non-Hodgkin lymphoma. Three cases have gone to trial and in each one, juries returned verdicts and tens of millions of dollars in damages for plaintiffs.īayer is dealing with two separate sets of legal risks from Roundup, which it acquired as part of its $63 billion purchase of Monsanto in 2018. The company has said that decades of studies have shown Roundup and glyphosate are safe for human use.īut thousands of users have alleged it caused their non-Hodgkin lymphoma, a blood cancer. District Judge Vince Chhabria in San Francisco called the plan "clearly unreasonable."īayer said its new proposal was "designed to help the company achieve a level of risk mitigation that is comparable to the previously proposed national class solution." judge rejected Bayer's $2 billion class action proposal, which would have provided compensation in return for placing limits on lawsuits. ![]() The company also said it will reassess its efforts to settle around 30,000 ongoing claims by Roundup users who are alleging they have become sick from the product. residential market after a judge rejected a $2 billion plan to settle future claims alleging the herbicide causes cancer. May 26 (Reuters) - Bayer (BAYGn.DE) said on Wednesday it will review the future of its Roundup and other glyphosate-based weedkillers in the U.S.
0 Comments
Leave a Reply. |